These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33532178)

  • 1. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
    Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
    Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
    Song Y; Zhao M; Wu Y; Yu B; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
    Huang L; Fu L
    Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
    Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
    Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
    J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase.
    Liu Y; Jenkins B; Shin JL; Rohrschneider LR
    Mol Cell Biol; 2001 May; 21(9):3047-56. PubMed ID: 11287610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
    Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
    Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
    Calligari P; Santucci V; Stella L; Bocchinfuso G
    Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
    Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
    Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor.
    Yart A; Laffargue M; Mayeux P; Chretien S; Peres C; Tonks N; Roche S; Payrastre B; Chap H; Raynal P
    J Biol Chem; 2001 Mar; 276(12):8856-64. PubMed ID: 11134009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of SHP2 and its role in cancer.
    Asmamaw MD; Shi XJ; Zhang LR; Liu HM
    Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of PD-1 Blockade in Cancer Immunotherapy.
    Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
    Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.
    Kong J; Long YQ
    RSC Med Chem; 2022 Mar; 13(3):246-257. PubMed ID: 35434626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to overcome drug resistance using SHP2 inhibitors.
    Liu M; Gao S; Elhassan RM; Hou X; Fang H
    Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.